ImpediMed Limited (ASX.IPD) today announced the receipt of a $1.8 million cash refund related to the R&D Tax Incentive.
The cash rebate is related to expenditure on eligible Australian and international R&D activities during the 2021 financial year.
For more information, download the attached PDF.
Download this document
